IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:
- Raymond W. Cohen, Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 10:15 am PDT at the Encore in Las Vegas.
- Cohen is also scheduled to present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 am EDT at the Grand Hyatt in New York City.
To access the live webcast of the presentations at the aforementioned conferences, please visit the Events & Presentations page of the Investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the Company's website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM® System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.